Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Clinical Trials in Egypt / NCT07069816
Starting soon Observational

Esophageal Motility and Gastric Emptying Disorders Among Different Thyroid Dysfunction

NCT07069816 · tracked via the Priya Life Science Egypt tracker
Sponsor
Assiut University
Phase
Observational
Started
2025-08-01
Last updated
2025-07-17

Condition(s) studied

GI Disorders

Investigational drug(s) / intervention(s)

ScintigraphyScintigraphy

Scintigraphy: non invasive method in which the test meals and acquisition procedures have been standardized and the results are largely operator independent

Scintigraphy: Non invasive method in which the test meals and acquisition procedures have been standardized

Study summary

Detect prevalence of different gastroparesis symptoms among different thyroid disorders Effect of thyroid disorders either hypothyroidism, hyperthyroidism and subclinical disorders in upper gastro motility

Eligibility

Sex
ALL
Min age
18 Years
Max age
60 Years
Healthy volunteers
No
Inclusion Criteria: * all patient diagnosed as hypothyroidism, hyperthyroidism and subclinical thyroid disorders in diabetic and endocrinological centre in Assiut university hospitals, age above 18 years Exclusion Criteria: * patients take any drugs affect GIT motility Patients with acute infection Patients with major surgeries or recent trauma less than 6 months Patients known to have malignancy Patients with previous history of bariatric surgery Patients with history of liver cirrhosis or inflammatory bowel diseases

Primary outcome measure(s)

  • Detect prevalence of different gastroparesis symptoms among different thyroid disorders — Baseline

Trial sites (1)

FacilityCityRegionStatus
Esraa Asyut Egypt

More Assiut University trials in Egypt

Combined Hystroscopic and Laparoscopic Repair of CS Scar Disorder Recruiting
The Outcome of Inserting Intercostal Tube or Pleurodesis for Malignant Pleural Effusion Starting soon
Maternal Iron Deficiency and/or Iron Deficiency Anemia to Neonatal Hemoglobin Concentration and Iron Stores Starting soon
Real-Time (TRUS) Guidance in Endoscopic Treatment of BPH Starting soon
Intraoperative Lidocaine Infusion Starting soon
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07069816 on ClinicalTrials.gov ↗ ← All trials in Egypt